Last reviewed · How we verify
rhTSH stimulation
Recombinant human thyroid-stimulating hormone (rhTSH) stimulates thyroid hormone production and uptake to enhance radioactive iodine accumulation in thyroid cancer cells.
Recombinant human thyroid-stimulating hormone (rhTSH) stimulates thyroid hormone production and uptake to enhance radioactive iodine accumulation in thyroid cancer cells. Used for Differentiated thyroid cancer requiring radioactive iodine therapy, Thyroid cancer with distant metastases.
At a glance
| Generic name | rhTSH stimulation |
|---|---|
| Also known as | Thyrogen |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Drug class | Recombinant hormone |
| Target | TSH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
rhTSH is a recombinant form of the pituitary hormone that normally regulates thyroid function. In thyroid cancer patients, rhTSH stimulation increases thyroid-specific gene expression and radioiodine uptake in both normal and malignant thyroid tissue, improving the efficacy of radioactive iodine therapy. This approach allows for effective treatment while minimizing systemic radiation exposure compared to thyroid hormone withdrawal protocols.
Approved indications
- Differentiated thyroid cancer requiring radioactive iodine therapy
- Thyroid cancer with distant metastases
Common side effects
- Headache
- Nausea
- Fatigue
- Hypothyroid symptoms
Key clinical trials
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation (PHASE2)
- Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up (PHASE3)
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment (NA)
- Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study (EARLY_PHASE1)
- Hormone Evaluation in Artificial Reproductive Technology (NA)
- Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells (PHASE1)
- Estradiol and Progesterone Levels Following Frozen Embryo Transfer (PHASE4)
- Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |